J&J presents successful data from plaque psoriasis trial
Drug Discovery World
MARCH 13, 2024
Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor. at 16 weeks and 76.2% Across JNJ-2113 treatment groups, 58.6%
Let's personalize your content